Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Scynexis Inc
(NQ:
SCYX
)
1.335
-0.025 (-1.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Scynexis Inc
< Previous
1
2
3
4
Next >
SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024
August 09, 2024
SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
July 23, 2024
Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning!
Via
InvestorPlace
3 Stocks Under $10 With the Potential for Massive Gains
July 22, 2024
Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries.
Via
InvestorPlace
3 Dirt-Cheap Drug Developers With Blockbuster Potential
July 11, 2024
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.
Via
InvestorPlace
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
July 01, 2024
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.
Via
InvestorPlace
Should you consider SCYNEXIS INC (NASDAQ:SCYX) for growth investing?
May 20, 2024
Exploring SCYNEXIS INC (NASDAQ:SCYX)'s growth characteristics.
Via
Chartmill
SCYNEXIS: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
Looking Into SCYNEXIS's Return On Capital Employed
April 03, 2023
Via
Benzinga
Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025
May 31, 2024
Read here about the top under-$10 growth stocks primed for financial success through strategic partnerships and innovative product offerings.
Via
InvestorPlace
3 Stocks Under $10 With Mammoth Growth Prospects
May 23, 2024
Learn more about the growth stocks under $10 with progressive fundamentals in the healthcare and technology sectors.
Via
InvestorPlace
SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024
May 08, 2024
SCYX stock results show that SCYNEXIS beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023
March 28, 2024
SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
5 Value Stocks To Watch In The Healthcare Sector
January 29, 2024
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
January 08, 2024
Via
Benzinga
Why Resources Connection Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
January 04, 2024
Shares of Resources Connection, Inc. (NASDAQ: RGP) rose sharply in pre-market trading following better-than-expected results for its second quarter.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 03, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 02, 2024
Via
Benzinga
Gold Moves Lower; TransCode Therapeutics Shares Surge
September 25, 2023
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday. The Dow traded down 0.07% to 33,939.93 while the NASDAQ rose 0.24% to...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
September 25, 2023
Via
Benzinga
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 25, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Via
Benzinga
Nasdaq Turns Higher; SCYNEXIS Shares Plunge
September 25, 2023
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite trading higher on Monday. The Dow traded down 0.01% to 33,962.53 while the NASDAQ rose 0.26% to 13,246.15. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Are Antifungal Focused Scynexis Stock Plunging Today?
September 25, 2023
Scynexis Inc (NASDAQ: SCYX) is voluntarily recalling its antifunga
Via
Benzinga
U.S. Stocks Open Lower; Chicago Fed Index Falls In August
September 25, 2023
U.S. stocks traded mostly lower this morning, with the Dow Jones trading falling around 80 points on Monday. Following the market opening Monday, the Dow traded down 0.26% to 33,875.83 while the NASDAQ...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 25, 2023
Via
Benzinga
Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now
August 28, 2023
While the very concept of penny stocks to buy is treacherous, these analyst-backed ideas could be enticing for the smart speculator.
Via
InvestorPlace
Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
August 16, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 15, 2023
Via
Benzinga
Dow Rises 100 Points; Accelerate Diagnostics Shares Spike Higher
March 30, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 100 points on Thursday. The Dow traded up 0.31% to 32,819.16 while the NASDAQ rose 0.63% to 12,001.83. The S&P...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
March 30, 2023
Via
Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 30, 2023
Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.